摘要
目的探讨不同剂量肺表面活性物质联合INSURE技术对新生儿呼吸窘迫综合征治疗效果的影响。方法选取2017年1月-2020年9月就诊于安徽省第二人民医院NICU 80例新生儿呼吸窘迫综合征为研究对象。按照随机数字法分为观察组和对照组,各40例,2组均给予INSURE技术注入肺表面活性物质(PS)治疗,其中对照组给予PS 70 mg/kg.观察组给予PS 100 mg/kg,比较2组患儿治疗前后的临床疗效、血气分析指标、氧合指数用氧时间、住院时间以及并发症发生率。结果治疗后观察组(100.0%)临床总有效率高于对照组(85.0%,P<0.05);观察组用氧时间明显短于对照组(P<0.05);2组住院时间比较差异无统计学意义(P>0.05);2组治疗前血气分析结果及氧合指数比较差异无统计学意义(均P>0.05);治疗后血气分析结果及氧合指数均较治疗前明显改善,其中PaO_(2)上升,PaCO2下降,pH改善,差异有统计学意义(均P<0.05);观察组PaO_(2)[(77.55±5.79)mm Hg,1 mm Hg=0.133 kPa]明显高于对照组[(72.45±4.37)mm Hg],PaCO2[(39.45±2.45)mm Hg]低于对照组[(40.88±2.32)mm Hg],观察组pH(7.36±0.02)改善优于对照组(7.35±0.02),差异均有统计学意义(均P<0.05);观察组并发症发生率(12.5%)低于对照组(35.0%,P<0.05)。结论100 mg/kg PS联合INSURE技术治疗新生儿呼吸窘迫综合征,可显著改善患者临床症状,改善氧合指数,减少用氧时间及临床并发症。
Objective To investigate the clinical effect of different doses of pulmonary surfactant(PS) combined with INSURE technology in the treatment of neonatal respiratory distress syndrome. Methods A total of 80 neonatal respiratory distress syndrome cases in the NICU of Anhui No.2 Provincial People’s Hospital from January 2017 to September 2020 were selected as the research objects. According to the random number method, the children were divided into two groups with 40 cases in each group. Both groups were treated with INSURE technology and injected with PS. The control group was given 70 mg/kg PS, and the experimental group was given 100 mg/kg PS. The clinical efficacy, blood gas analysis index, oxygenation index, oxygen duration, length of hospital stay and incidence of complications of the two groups were compared before and after treatment. Results The total effective rate of the experimental group(100.0%) was higher than that of the control group(85.0%), and the difference was statistically significant(P<0.05). The duration of oxygen use in the experimental group was significantly shorter than that of the control group(P<0.05). No difference was observed in the length of stay between the two groups(P>0.05). No significant difference was observed in blood gas analysis and oxygenation indices between both groups before treatment(P>0.05). The blood gas analysis and oxygenation index after treatment were significantly improved compared with those before treatment;that is, PaO2 increased, PaCO2 decreased, and pH improved(all P<0.05). The PaO2 [(77.55±5.79) mm Hg] of the experimental group was significantly higher than that of the control group [(72.45±4.37) mm Hg], whilst the PaCO2 [(39.45±2.45) mm Hg] was lower than that of the control group [(40.88±2.32) mm Hg]. The pH of the experimental group(7.36±0.02) was significantly better than that of the control group(7.35±0.02), with statistically significant differences(P<0.05). The complication rate of the experimental group(12.5%) was lower than that of the con
作者
冯敏
罗兵
FENG Min;LUO Bing(Department of Pediatrics,Anhui No.2 Provincial People's Hospital,Hefei,Anhui 230000,China;不详)
出处
《中华全科医学》
2021年第10期1689-1692,共4页
Chinese Journal of General Practice
基金
安徽省自然科学基金项目(KJ2019A1099)。
关键词
肺表面活性物质
新生儿
呼吸窘迫综合征
气管插管
经鼻持续气道正压通气
临床疗效
Pulmonary surfactant
Newborn
Respiratory distress syndrome
Tracheal intubation
Nasal continuous positive airway pressure ventilation
Clinical curative effect
